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One hallmark of human immunodeficiency virus type 1 (HIV-1) infection is the dysregulation of cytokine
gene expression in T cells. Transfection of T cells with human T-cell leukemia type 1 or 2 transactivator results
in the induction of the T-cell-restricted cytokine interleukin-2 (IL-2) and its receptor (IL-2R). However, no
T-cell-specific factor(s) has been directly linked with the regulation of IL-2 and IL-2R transcription by
influencing the promoter activity. Thymocytes from SATB1 (special AT-rich sequence binding protein 1)
knockout mice have been shown to ectopically express IL-2R, suggesting involvement of SATB1 in its negative
regulation. Here we show that SATB1, a T-cell-specific global gene regulator, binds to the promoters of human
IL-2 and IL-2R and recruits histone deacetylase 1 (HDAC1) in vivo. SATB1 also interacts with Tat in
HIV-1-infected T cells. The functional interaction between HIV-1 Tat and SATB1 requires its PDZ-like domain,
and the binding of the HDAC1 corepressor occurs through the same. Furthermore, Tat competitively displaces
HDAC1 that is bound to SATB1, leading to increased acetylation of the promoters in vivo. Transduction with
SATB1 interaction-deficient soluble Tat (Tat 40-72) and reporter assays using a transactivation-negative
mutant (C22G) of Tat unequivocally demonstrated that the displacement of HDAC1 itself is sufficient for
derepression of these promoters in vivo. These results suggest a novel mechanism by which HIV-1 Tat might
overcome SATB1-mediated repression in T cells.
Interleukin-2 (IL-2) is the key growth factor for T lympho-
cytes that participates in the regulation of the duration and
magnitude of the T-cell immune response (29). The IL-2 re-
ceptor (IL-2R) is present on the T-cell surface and is involved
in the IL-2-mediated signal transduction for T-cell prolifera-
tion, differentiation, and functional activation (13, 29). The
physiologically active, high-affinity form of IL-2R is comprised
of an inducible 55-kDa protein encoded by the T-cell activa-
tion antigen or CD25 or IL-2R gene, a constitutive 70-kDa
protein encoded by the IL-2R gene, and a gamma chain that
is common with other receptors, such as IL-7R (13). The ex-
pression of both IL-2 and IL-2R is tightly regulated and is
induced by agents that mimic antigenic stimulation, including
mitogens and lymphotropic retroviruses (13, 19, 29, 46). All
transcription factors implicated in IL-2 (38) induction are
ubiquitously expressed, and no T-lineage-specific factor that
regulates its expression has yet been identified. IL-2R is ec-
topically expressed in SATB1 (special AT-rich sequence bind-
ing protein 1) knockout mice, suggesting involvement of
SATB1 in its regulation (2). In regard to the mouse IL-2R
locus, SATB1 recruits histone deacetylase 1 (HDAC1) from
the nucleosome remodeling and histone deacetylase complex
to its intronic binding site and mediates the deacetylation of
histones over long distances within the locus (53). Since
SATB1 is a T-lineage-specific global suppressor (2, 53), we
explored its involvement in the regulation of human IL-2 and
IL-2R expression. SATB1 participates in the maintenance of
chromatin architecture in a cell-type-specific manner by orga-
nizing it into domains via periodic anchoring of base-unpairing
regions (BURs) to the nuclear matrix (6). In thymocyte nuclei,
SATB1 has a cage-like network distribution circumscribing
heterochromatin and selectively tethers BURs onto its net-
work resulting in coordinated regulation of distant genes (6).
Studies of SATB1 knockout mice indicate that 2% of the
genes, including cytokine receptor genes, were derepressed at
appropriate stages of T-cell development in a spatiotemporal
manner. The maturation of thymocytes was blocked mainly at
the CD4 CD8 double-positive stage, indicating a key role
for SATB1 in T-cell development and differentiation (2).
SATB1 regulates large chromatin domains by acting as a
“landing platform” for several chromatin remodeling enzymes
in T cells (53). SATB1 may also regulate gene expression by
directly influencing the promoter activity. SATB1 binds di-
rectly to multiple elements in the gp91(phox) promoter and
thereby negatively regulates gp91(phox) expression (22).
Dysregulation of cytokine gene expression is a hallmark of
human immunodeficiency virus type 1 (HIV-1) infection (5, 8).
The retroviral transactivator protein (Tat) is implicated in
much of the transcriptional dysregulation in host T cells (5, 7).
Transfection of T cells with human T-cell lymphotropic virus
type 1 or 2 (HTLV-1 or -2) transactivator (Tax) results in the
induction of the IL-2 and IL-2R (19). Consistent with this,
interaction of inducible nuclear proteins with discrete pro-
moter elements has been implicated in the regulation of IL-
2R transcription (28, 30). However, the identity of the host
factor has remained unknown, especially since NF-B-inde-
pendent activation was observed (35). Here we show that
SATB1, a T-cell-specific global gene regulator, binds to the
human IL-2 and IL-2R promoters and recruits HDAC1 in
vivo, causing the downregulation of the promoters. We found
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functional interaction between HIV-1 Tat and SATB1 both in
vitro and in vivo, and we show that this interaction occurs via
the PDZ-like domain of SATB1 and the HDAC1 corepressor
also binds through the same. Our results suggest a novel mech-
anism by which HIV-1 Tat induces the expression of IL-2 and
IL-2R via displacement of the SATB1-bound HDAC1 core-
pressor.
MATERIALS AND METHODS
EMSA. Electrophoretic mobility shift assays (EMSA) were performed as de-
scribed previously (27). The recombinant DNA-binding C-terminal half of
SATB1 was expressed and purified as a glutathione S-transferase (GST) fusion
and purified as described previously (10). Binding reactions were performed in a
10-l total volume containing 10 mM HEPES (pH 7.9), 1 mM dithiothreitol, 50
mM KCl, 2.5 mM MgCl2, 10% glycerol, 0.5 g of double-stranded poly(dI-dC),
10 g of bovine serum albumin, and 1 to 5 g of the recombinant protein.
Samples were preincubated at room temperature for 5 min prior to the addition
of the 32P-labeled probe. As probes we used 32P-labeled PCR-amplified products
of IL-2 promoter and IL-2R promoter sequences. Some of the longer products
were also digested with restriction enzymes, and the fragments were used as
probes following gel purification. After 15 min of incubation at room tempera-
ture, the products of such binding reactions were then resolved by 6% native
polyacrylamide gel electrophoresis (PAGE). The gels were dried under vacuum
and exposed to X-ray film.
In vitro binding and displacement assays. HEK 293 cells were transfected with
FLAG-HDAC1 (provided by S. Schreiber), and lysate was incubated at 4°C for
1 h with 10 l of M2-FLAG affinity gel (Sigma). Beads were washed three times
in buffer containing 50 mM NaCl phosphate buffer. These beads were incubated
with 5 and 10 g of GST-Tat protein at 4°C for 8 h. Purified GST was used as a
control. Bound proteins were eluted with sodium dodecyl sulfate (SDS)-loading
buffer and analyzed by Western blotting with anti-SATB1 antibody or, in the case
of in vitro-translated proteins, by exposure to X-ray film (Kodak).
Yeast two-hybrid analysis. The DraI fragment of human SATB1 cDNA en-
coding near full-length SATB1, the PDZ domain, and the matrix attachment
region (MAR)-binding domain plus homeodomain (MDHD) domain of
SATB1 were fused separately with the GAL4 activation domain (AD) in
pGAD424 vector (Clontech) (16). Full-length Tat was cloned as a fusion with the
GAL4 DNA-binding domain (DBD) in the pAS2.1 vector (Clontech). The AD
and DBD fusion constructs were cotransformed in a pairwise fashion in yeast
strain AH109 (Clontech) as described previously (16) and assayed for protein-
protein interaction by using standard protocols, with HIS3 and LacZ as the
proteins encoded by the reporter genes. The liquid -galactosidase (-Gal) assay
was performed according to the manufacturer’s protocol (Pierce), and the values
represent an average of results from two independent experiments.
PBMC isolation, activation, and infection. Human peripheral blood mononu-
clear cells (PBMCs) were isolated from blood samples of normal seronegative
donors. The cells were activated with phytohemagglutinin (5 g/ml) and kept for
36 to 48 h. The activated cells were infected with HIV-1 at a multiplicity of
infection of 0.1 and were maintained in media containing human IL-2 at 20 U/ml
(Roche Applied Bioscience, Mannheim, Germany). The infection was monitored
by HIV-1 p24 antigen capture enzyme-linked immunosorbent assay of culture
supernatants (Perkin-Elmer Life Science, Boston, Mass.).
Coimmunoprecipitation. One hundred micrograms of protein in nuclear ex-
tract was diluted by adding 2 volumes of IP-150 buffer and precleared with rabbit
immunoglobulin G (IgG; Sigma) and protein A/G plus beads (Pierce). Pre-
cleared extract was then incubated with either polyclonal anti-SATB1 (1:50),
anti-Tat antibody (1:50; National Institutes of Health AIDS reagent program)
(20), anti-HDAC1 (1:25; Santa Cruz), or anti-FLAG M2 monoclonal antibody
(Sigma). Protein-antibody complexes were recovered with protein A/G beads
and washed in phosphate-buffered saline (PBS) containing 0.5% NP-40. Soluble
proteins were obtained with SDS loading buffer and identified by Western anal-
ysis with anti-HDAC1, anti-SATB1, and anti-Tat antibodies.
ChIP. CEM-GFP cells were infected with the HIV-1 NL4.3 virus isolate (1) at
a multiplicity of infection of 0.1 as described previously (32). We consistently
observed that at least 70% of the infected cell population exhibited long terminal
repeat (LTR)-driven green fluorescent protein expression. Uninfected and in-
fected cells were cross-linked for 15 min at 37°C by adding formaldehyde (to a
final concentration of 1%) directly to the culture medium, and chromatin im-
munoprecipitations (ChIP) were carried out as described previously (21). For
immunoprecipitation of chromatin we used various antibodies as described
above and also the anti-H3 acetylated lysine 9 (acetyl-H3K9) from Upstate
Biotechnology (Lake Placid, N.Y.). One-fiftieth of the DNA from each pool was
PCR amplified in 50-l reaction mixtures containing 50 mM KCl, 10 mM Tris-
HCl, 1.5 mM MgCl2, 0.1% Triton X-100, 1.0 U of Taq DNA polymerase (Pro-
mega), and a 1 M concentration of each of the IL-2 promoter primer pairs or
IL-2R promoter primers using 1 cycle of 95°C for 5 min and 30 cycles of 95°C
for 1 min, 48°C for 1 min, and 72°C for 1 min. PCR products were resolved by
native PAGE, stained with SYBR gold (molecular probes) and visualized under
UV illumination. Quantitative PCRs were performed using the SYBR green IQ
supermix (Bio-Rad) and the ICycler IQ real-time thermal cycler (Bio-Rad). The
changes in threshold cycle (CT) values were calculated as follows: CT  CT
Target 	 CT Input.
Tat transduction. Wild-type Tat containing the 86-amino-acid Tat protein of
HIV-1 molecular clone NL4.3, Tat 1–48, Tat 40–72, and C22G mutant Tat were
expressed as GST fusions in BL21 cells and purified using glutathione Sepharose
(Amersham Biosciences) affinity chromatography. Tat was cleaved on the affinity
column from the GST tag by using thrombin. GST was eluted by using glutathi-
one-containing elution buffer. All recombinant proteins were dialyzed against
PBS, sterilized by passing through a 0.22 m-pore-size filter, and used immedi-
ately. Jurkat cells were transduced essentially as described previously (48), with
few modifications. Briefly, cells were resuspended to a density of 5 
 105 per ml
in fresh RPMI 1640 medium supplemented with 10% fetal calf serum, 100 M
chloroquine, and 200 ng of recombinant Tat protein/ml. Cells were incubated for
4 h at 37°C in a 5% CO2 atmosphere. Cells were then harvested by centrifugation
and washed twice with PBS. Nuclear extracts were prepared using 0.4 M NaCl-
containing extraction buffer as described previously (27), and total RNA was
isolated using Trizol (Invitrogen). An aliquot of transduced cells was fixed by
using 0.4% paraformaldehyde and stained by using either polyclonal anti-Tat
antibody or rabbit IgG as a control. Cells were then incubated with anti-rabbit-
fluorescein isothiocyanate (BD Biosciences) and acquired on a flow cytometer
(FACSvantage; BD Biosciences). The efficiency of transduction was expressed as
the percentage of cells stained with anti-Tat antibody.
Luciferase reporter assays. Luciferase assays were performed using Luc Lite
reagent (Perkin Elmer), and luciferase activity was measured using Top Count
(Packard). The 555-bp IL-2R promoter region (9) spanning base pairs 	445 to
110 was PCR amplified and cloned into pGL3 basic vector. The IL-2 promoter
(45)-luciferase reporter construct was obtained from K. McGuire. For cotrans-
fections we used p3XFLAG-CMV10-SATB1, pCDNA3.1-Tat (25), and pBJ5-
HDAC1 at 1 to 2 g/well either singly or in different combinations along with the
reporter constructs at 1 g/well. HEK 293 cells were seeded at 0.2
 106 cells per
well and transfected using Lipofectamine 2000 reagent (Invitrogen). Forty hours
after transfection, the culture medium was removed; cells were washed with PBS
and processed further. Cells were resuspended in 100 l of reporter lysis buffer
and kept at 	70°C. After being freeze-thawed twice, the lysate was clarified by
spinning at 8,000 
 g for 15 min. For accurate quantitation of luciferase activity,
an equal amount (50 g) of the protein was assayed. Protein concentrations in
the lysates were measured using Bradford reagent (Bio-Rad). Fold differences
were calculated by normalizing the treatment values to the control value. The
statistical significance of differences between the treatment groups was calcu-
lated using one-way analysis of variance (SigmaStat; SPSS Inc.), and the ob-
served P values were always less than 0.001.
RESULTS
SATB1 directly binds to the upstream regulatory region of
IL-2R. We first investigated whether SATB1 binds directly to
the enhancer elements within the upstream regulatory ele-
ments of human IL-2R by using EMSA. We generated a
series of radiolabeled probes spanning the entire length of the
1.3-kb IL-2R promoter (9) (Fig. 1A). Of the seven probes
used, only one probe (probe 4) containing the inverted direct
repeat (IDR) (9, 19) in the IL-2R promoter was bound by
SATB1 (Fig. 1B, lanes 24 and 25) but not by GST–poly(ADP-
ribose) polymerase (PARP) (Fig. 1B, lanes 22 and 23) or GST
alone (Fig. 1B, lanes 21 and 22). We next examined whether
SATB1 is complexed with the IL-2R promoter in vivo by
performing a ChIP assay using chromatin from CEM-GFP
cells. We used chromatin from CEM-GFP, a stable CD4
T-cell line containing a plasmid encoding the green fluorescent
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protein driven by the HIV-1 LTR promoter (17). This cell line
has been used widely as a reporter cell line to monitor HIV
infection. The cross-linked chromatin was immunoprecipitated
with anti-SATB1, and the same set of primers was used for
PCR amplification following reversal of cross-links. The PCR
analysis was performed in different numbers of cycles ranging
from 30 to 40. We observed that while most of the primer sets
yielded amplified products at 35 and 40 cycles, only probe 4
primers amplified the chromatin at 30 cycles (Fig. 1C, lane 19),
suggesting specific binding in vivo. We further confirmed the
specificity of this observation by carrying amplification at 30
cycles and using chromatin immunoprecipitated by control
rabbit IgG and anti-SATB1 (Fig. 1D, top and middle panels).
We did not observe any amplification of this pool of chromatin;
however, probe 4 primers amplified a specific product with
anti-SATB1 immunoprecipitated chromatin (Fig. 1D, lane 4).
To further narrow down the binding site and to verify the
contribution of IDRs, we digested the probe 4 region with AluI
and XmnI (Fig. 1E). The resulting 103-bp fragment (probe 8)
corresponding to base pairs 	323 to 	226 of the IL-2R
promoter containing both IDRs and the B-like motif was
radiolabeled and used for EMSA. SATB1 bound to this region
in a dose-dependent manner (Fig. 1F, lanes 6 and 7). This
region contains an 11-bp motif resembling the NF-B consen-
sus that is implicated in the inducible expression of IL-2R
(28, 30). We therefore investigated whether this motif is bound
by SATB1 by using competition assays. A 16-bp double-
stranded oligonucleotide corresponding to base pairs 	267 to
	252 of the IL-2R upstream region bearing the B-like motif
effectively competed binding by SATB1 in a dose-dependent
manner (Fig. 1F, lanes 8 to 10). However, SATB1 failed to
bind directly to this duplex B oligonucleotide (probe 9, Fig.
1F, lanes 12 to 14), suggesting that its binding site overlaps with
the B-like motif in the upstream region of IL-2R. The 3 half
of the duplex B fragment overlaps with the first eight bases of
the right half of IDR. It should be noted that SATB1 prefers to
bind to DNA substrate harboring at least two binding sites that
are separated by a 10- to 30-bp spacer (our unpublished ob-
servations). To further verify whether the IDR is essential for
binding of SATB1 to the IL-2R promoter region, we per-
formed EMSA analysis using smaller portions of the region
corresponding to probe 4. The slightly shorter version of this
probe (probe 10, spanning base pairs 	445 to 	167) was also
bound by SATB1 (Fig. 1G, lanes 3 and 4). Two overlapping
halves of this region (probe 11, spanning base pairs 	445 to
	243, and probe 12, spanning base pairs 	295 to 	167) were
bound by SATB1 (Fig. 1G, lanes 8, 11, and 12). Interestingly,
this overlapping region contained the IDR. We therefore pre-
pared deletions in these probes wherein the IDR was elimi-
nated (probe 13, spanning base pairs 	445 to 	294, and probe
14, spanning base pairs 	240 to 	167) and monitored SATB1
binding by using EMSA. SATB1 binding activity was abolished
when IDR was eliminated from this region (Fig. 1G, lanes 15,
16, 19, and 20). Collectively, these results suggest that the IDR
in the IL-2R promoter is a preferred target for SATB1.
SATB1 directly binds to the upstream regulatory region of
IL-2. Since a common transcription factor is implicated in the
inducible expression of IL-2 and its receptor (44), we further
investigated whether SATB1 is involved in the regulation of
IL-2 by binding directly to the upstream regulatory elements of
human IL-2. We analyzed the SATB1 binding sites in the IL-2
promoter using various restriction fragments of the promoter
(45). The EMSA analysis with these probes suggested the
presence of a binding site in each of the two halves of the
promoter (Fig. 2A). The presence of multiple SATB1 binding
sites in promoters is not unique since SATB1 is known to bind
directly to multiple elements within the gp91(phox) promoter
in vitro (22). We next examined whether SATB1 is complexed
with the IL-2 promoter in vivo by performing a ChIP assay.
The cross-linked chromatin from CEM-GFP cells was immu-
FIG. 1. SATB1 binds to the human IL-2R promoter in vitro and in vivo. (A) Schematic representation of the IL-2R 1.3-kb promoter
sequence spanning the base pair 	1240 to 110 region. The positions of the probes used for EMSA and ChIP are as indicated. (B) Mapping of
the binding site of SATB1 in the IL-2R promoter region. EMSA analysis was performed using bacterially expressed and purified GST-SATB1
and 32P-end-labeled probes. Probes 1 (	1240F to	937R), 2 (	957F to	725R), 3 (	746F to	473R), 4 (	493F to	167R), 5 (	187F to110R),
6 (	957F to 	473R), and 7 (	1240F to 	725R) were amplified by PCR using specific primer sets. The probes were incubated with 1 g (lanes
2, 5, 8, 11, 14, 17, and 24), 2 g of GST-SATB1 (lanes 3, 6, 9, 12, 15, 18, and 25), 1 to 2 g of GST alone (lanes 20 and 21), and 1 to 2 g of
GST-PARP (lanes 22 and 23). DNA-protein complexes were resolved on native polyacrylamide gels. Usage of probes was as indicated below the
lanes. (C) SATB1 binds to the IL2R promoter in vivo. DNA purified from CEM-GFP chromatin immunoprecipitated with anti-SATB1 using
seven sets of primers encompassing the entire promoter region of IL-2R were subjected to 30, 35, and 40 cycles of PCR amplification. Usage of
probes was as indicated above the lanes. (D) SATB1 binds specifically to the base pair 	493 to 	167 region (probe 4) in the IL-2R promoter
in vivo. The DNA in CEM-GFP cells was chromatin immunoprecipitated with rabbit IgG (R-IgG, top panel) and anti-SATB1 (middle panel) and
was subjected to 30 cycles of PCR using a panel of primers as described above. The lower panel depicts the PCR-amplified DNA from total
chromatin as a control. (E) Schematic representation of the IL-2R base pair 	493 to 	167 promoter sequence with positions of the probes used
for EMSA. The relative positions of useful restriction sites are as indicated. The IDRs are underlined, and the position of the B-like element is
also indicated. (F) An SATB1 binding site encompasses the IDRs in IL-2R promoter. EMSA using bacterially expressed and purified SATB1 and
the 32P-end-labeled 326-bp probe 4 (lanes 1 to 4) or 103-bp probe 8 generated by AluI and HinfI digestion of the same followed by polyacrylamide
gel purification (base pair 	328 to 	226 fragment). GST-SATB1 was used at 0.5 (lane 2), 1 (lanes 3 and 6), and 2 g (lanes 4 and 7 to 10) in the
binding reactions. Incubation of the reaction mixture with 10-, 50-, and 100-fold concentrations of cold B duplex oligonucleotide (oligo) as a
competitor DNA resulted in loss of binding (lanes 8, 9, and 10, respectively). Similarly, increasing amounts of SATB1 (lane 12, 13, and 14) were
incubated with the 32P-end-labeled duplex B oligonucleotide (probe 9). (G) IDR is essential for binding of SATB1 to the IL-2R promoter
region. EMSA analysis was performed using bacterially expressed and purified GST-SATB1 and 32P-end-labeled probes. Probe 10 (	445F to
	167R), 11 (	445F to 	243R), 12 (	295F to 	167R), 13 (	445F to 	294R), and 14 (	240F to 	167R) were PCR amplified using specific
primer sets. The probes were incubated with 1 g of GST-SATB1 (lanes 3, 7, 11, 15, and 19), 2 g of GST-SATB1 (lanes 4, 8, 12, 16, and 20),
and 2 g of GST alone (lanes 2, 6, 10, 14, and 18). DNA-protein complexes were resolved on native polyacrylamide gels and visualized by
autoradiography. Usage of probes was as indicated at the top. Probes 13 and 14 are essentially the same as probes 10 and 11, respectively, except
that they lack the IDR.
VOL. 25, 2005 HIV-1 Tat DISRUPTS SATB1-HDAC1 COMPLEX 1623
noprecipitated with anti-SATB1 and used for PCR amplifica-
tion following reversal of cross-links. We used two-primer sets
specific for the distal (P1) and proximal (P2) halves of the
promoter and performed ChIP analysis using anti-SATB1. In-
terestingly, only the P1 primer set (Fig. 2B, lane 1, upper
panel) and not P2 (Fig. 2B, lane 1, lower panel) yielded a
specific product at 30 cycles of amplification. This binding is
very specific since, although both the distal and proximal re-
gions in the IL-2 promoter were bound by SATB1 in vitro, only
the distal promoter was bound in vivo. Although amplification
product using the P2 primer set was detected at cycles num-
bered 35 and above, it is possible that SATB1 is actually bound
to only the distal promoter in vivo. While searching for canon-
ical binding elements within the distal promoter, we came
across a 37-nucleotide contiguous stretch of As, Ts, and Cs that
agrees with the definition of the ATC context (10). The ATC
context containing overlapping regions F4 (base pairs 	477 to
	345) and F5 (base pairs 	626 to 	441) were amplified by
PCR using specific primers and labeled using 32P-dCTP.
EMSA analysis using GST-SATB1 demonstrated binding of
SATB1 to both these halves of the distal promoter (Fig. 2D,
lanes 3, 4, 7, and 8). The overlapping region between these two
probes corresponds to the 37-mer ATC region. To confirm
whether SATB1 specifically recognizes the ATC context, we
disrupted the continuity of ATC by changing A to G at two
sites (Fig. 2E). EMSA analysis using the end-labeled wild-type
FIG. 2. SATB1 binds to the human IL-2 promoter in vitro and in vivo. (A) Schematic representation of 0.62-kb IL-2 promoter sequence
spanning base pair 	626 to 	2 region of translation start site. The positions of the probes used for EMSA and ChIP are as indicated. (B) SATB1
binds to the IL-2 promoter in vitro. Mapping of the binding site of SATB1 in the IL-2 promoter region (IL2P) was performed by EMSA analysis
as described in Materials and Methods, using 2 g of bacterially expressed and purified GST-SATB1 and 32P-labeled probes. An equal amount
of GST was used as a control in binding reactions. The probes were generated using AflIII restriction digestion (F2 and F3) or PCR amplification
using specific primer pairs (full length and P1). (C) In vivo binding of SATB1 to the distal IL-2 promoter. Anti-SATB1 immunoprecipitated
chromatin from CEM-GFP cells was amplified with P1 (top) and P2 (bottom) primer sets for 30 (lane 1), 35 (lane 2), and 40 (lane 3) cycles. ChIP
analysis was again performed using rabbit IgG (R-IgG, lane 4, upper panel) and anti-SATB1 (lane 5, upper panel) and subjected to 30 cycles of
PCR amplification with the P1 primer set. Input (lanes 4 and 5, bottom panel) denotes amplification of the DNA in soluble chromatin prior to
immunoprecipitation. (D) SATB1 binds to the 37-mer ATC context present in the distal promoter (P1 region) of the IL-2 promoter. The ATC
context containing overlapping regions F4 (	477 to 	345) and F5 (	626 to 	441) were amplified by PCR using specific primers and labeled using
[32P]dCTP. EMSA analysis was performed using 1 (lanes 3 and 7) or 2 (lanes 4 and 8) g of GST-SATB1 or 2 g of GST alone (lanes 2 and 5).
Wild-type (Wt) and mutant (Mut) forward and reverse 37-mer oligonucleotides were annealed and end labeled with [32P]ATP. Wild-type annealed
double-stranded 37-mer oligonucleotide (corresponding to nucleotides 	477 to 	441 of the IL-2 promoter) displays perfect ATC context whereas
the mutant has two A-to-G changes that disrupt the ATC context. Binding reactions were performed as described for F4 and F5. (E) Nucleotide
sequences of the wild-type and mutated 37-mer ATC context spanning the region from base pair 	477 to base pair –441 from the translation start
site of IL-2. The two mutated nucleotides are shown in boxes.
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and mutated 37-mer duplexes revealed specific binding of
SATB1 to the wild-type sequence (Fig. 2D, lanes 11 and 12),
whereas binding to the mutated 37-mer was completely abol-
ished (Fig. 2D, lanes 15 and 16). Thus, the ATC context span-
ning nucleotides 	477 to 	441 from the translation start site
of IL-2 harbors the preferred binding site for SATB1.
HIV-1 infection leads to upregulation of IL-2R and IL-2 in
T cells. The effect of HIV infection and Tat activity on upregu-
lation of IL-2 and its receptor occurs in the context of activated
T cells in synergy with T-cell activation signals (5, 8, 34, 49).
We therefore used activated PBMCs for infection. CEM-GFP
cells were also used as a representative CD4 T-cell line.
PBMCs and CEM-GFP cells were infected with the NL4.3
isolate of HIV-1 (1). Since SATB1 negatively regulates the
expression of the mouse IL-2R (53), we tested whether the
same is true in regard to the expression of the human IL-2R.
The IL-2R is induced in Tat/Tax transfected cell lines (28, 30,
46). We first monitored the effect of activation and viral infec-
tion on the expression of IL-2R by Western blot analysis. We
isolated PBMCs and treated them with phytohemagglutinin for
48 h. The resulting activated population was then infected with
HIV-1 isolate NL4.3. The activation was sustained by adding
IL-2 to the medium. We then analyzed the IL-2R levels by
immunoblot analysis of infected cells at day 7 and compared
them with those of uninfected activated cells (day 7) and con-
trol PBMCs. We observed that the level of IL-2R was in-
creased in both day 7 activated uninfected and day 7 activated
infected cells (Fig. 3A, upper panel, lanes 2 and 3, respec-
tively). Interestingly, the level of IL-2R protein was upregu-
lated by at least 2.5-fold in infected PBMCs compared to that
in the uninfected activated PBMCs (Fig. 3A). We also moni-
tored the expression of IL-2R by immunoblot analysis of
control and NL4.3-infected CEM-GFP total cell-free lysates.
We observed a sixfold induction of IL-2R expression in
NL4.3-infected CEM-GFP cells (Fig. 3A, upper panel, lane 5)
compared to that in uninfected CEM-GFP cells (Fig. 3A, up-
per panel, lane 4). Immunoblot analysis of actin was used as a
loading control (Fig. 3A, lower panel).
Since IL-2 is the principal cytokine in T cells that is regu-
lated almost exclusively at the level of transcription and is not
expressed in resting T cells (38), we monitored its expression in
PBMCs and CEM-GFP cells infected with NL4.3. Reverse
transcription-PCR (RT-PCR) analysis of mRNA isolated from
control (Fig. 3B, upper panel, lane 1), activated (Fig. 3B, upper
panel, lane 2), and activated infected (Fig. 3B, upper panel,
lane 3) PBMCs indicated that IL-2 is upregulated in activated
as well as infected PBMCs. RT-PCR analysis of mRNA iso-
lated from control (Fig. 3B, upper panel, lane 4) and infected
(Fig. 3B, upper panel, lane 5) CEM-GFP cells indicated that
IL-2 is upregulated at least 10-fold upon HIV-1 infection,
based on densitometric comparison of band intensities. The
expression of IL-2 mRNA was normalized with respect to that
of human GAPDH (Fig. 3B, lower panels). Thus, in uninfected
cells IL-2 and IL-2R seem to be repressed. Since we observed
that the upstream regulatory regions of both are directly bound
by SATB1 in vitro and in vivo, these results collectively impli-
cate SATB1 in the negative regulation of IL-2 and IL-2R in
PBMCs and the CEM-GFP human T-cell line.
SATB1 interacts with the HDAC1 corepressor via its PDZ-
like domain in vitro and in vivo. To test whether the negative
regulation by human SATB1 is manifested via recruitment of
the HDAC1 corepressor, we explored the possibility of their
direct interaction. We first performed coimmunoprecipitation
analysis using Jurkat cell extracts and with antibodies against
HDAC1, SATB1, and PARP. Analysis of the immunoprecipi-
tate revealed that SATB1 was immunoprecipitated by anti-
HDAC1 (Fig. 4A, lane 2) but not anti-PARP (Fig. 4A, lane 4).
HDAC1 forms a complex with SATB1 in human T cells in vivo
(Fig. 4A, upper and lower panels, lane 2), which is consistent
with previous studies showing complex formation between
mouse SATB1 and HDAC1 in vitro (53). We further delin-
eated the region of SATB1 that interacts with HDAC1. The
recombinant PDZ-like domain or MDHD domain constitut-
FIG. 3. Induction of IL-2R and IL-2 expression upon HIV infec-
tion. (A) Immunoblot analysis of total cell lysates from PBMCs (lane
1), activated PBMCs (lane 2), activated and HIV-1-infected PBMCs
(lane 3), uninfected CEM-GFP cells (lane 4), and NL4.3-infected
CEM-GFP cells (lane 5) using anti-IL-2R (upper panel) and anti-
actin (lower panel). (B) RT-PCR analysis of PBMCs (lane 1), activated
PBMCs (lane 2), activated and HIV-1-infected PBMCs (lane 3), un-
infected CEM-GFP cells (lane 4), and NL4.3-infected CEM-GFP cells
(lane 5) using primers specific for IL-2 (upper panel) and human
GAPDH (hGAPDH, lower panel).
FIG. 4. SATB1 directly interacts with the HDAC1 corepressor via
its PDZ domain in vitro and in vivo. (A) In vivo coimmunoprecipita-
tion analysis. SATB1 was immunoprecipitated from Jurkat cell extract
using anti-HDAC1 antibody and detected by immunoblot analysis us-
ing anti-SATB1 (lane 2). C, control extract alone (lane 1); PI, coim-
munoprecipitation using preimmune rabbit serum (lane 3). The lower
panel represents an immunoblot (IB) of the same samples with anti-
HDAC1, showing that HDAC1 is immunoprecipitated specifically by
anti-SATB1 (lane 2) and not by preimmune serum (lane 3). Immuno-
precipitation using anti-PARP (lane 4) serves as a negative control.
(B) Interacting domain of SATB1 with FLAG-tagged HDAC1 was
analyzed by a FLAG pulldown assay followed by immunoblotting using
anti-SATB1 as described in Materials and Methods. Anti-FLAG
pulled down the PDZ domain (lane 1) and full-length SATB1 (lane 2)
but not the MDHD domain (lane 3). The positions of molecular
weight standards are indicated on the right. The lower panel represents
an immunoblot with anti-HDAC1 as a loading control.
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ing the DNA-binding domain of SATB1 were separately incu-
bated with cell extract from HEK 293 cells transfected with the
construct expressing FLAG-HDAC1. Coimmunoprecipitation
analysis using anti-FLAG antibody showed that HDAC1 is
associated with the PDZ domain (Fig. 4B, lane 1) and full-
length SATB1 (Fig. 4B, lane 2) but not with its DNA-binding
domain (Fig. 4B, lane 3). Thus, human SATB1 may also act as
a transcriptional repressor by recruiting HDAC1 corepressor
to its specific genomic targets, including the IL-2 and IL-2R
promoters. From these observations, it is apparent that for
HIV-1 Tat to be able to upregulate the expression of genes
such as IL-2 and IL-2R, the repression mediated by SATB1
should be alleviated.
HIV-1 Tat associates with the PDZ-like domain of SATB1 in
vitro and in vivo. To investigate how Tat might overcome
negative regulation of IL-2R by SATB1, we tested whether
SATB1 specifically associates with HIV-1 Tat. Cell-free lysate
from Jurkat (Fig. 5A, lanes 1 to 4 and 6 to 9) or HEK 293 (Fig.
5A, lanes 11 to 14) cells was passed over GST-Tat bound
Sepharose matrix. The bound protein was eluted in a stepwise
FIG. 5. HIV-1 Tat physically interacts with SATB1 in vitro and in vivo. (A) SATB1 is eluted by GST-Tat affinity chromatography. Nuclear
extracts from Jurkat and 293 cells were passed separately on GST-Tat and GST affinity columns. Bound proteins were eluted with phosphate buffer
containing 1 M NaCl (lanes 3 and 13) or with reduced glutathione (lanes 9 and 14). Proteins from GST-bound Sepharose were eluted with reduced
glutathione only (lanes 5 and 10). Column input (lanes 1, 6, and 11), flowthrough (lanes 2, 7, and 12), and wash using phosphate-buffered saline
(lanes 4 and 8). (B) In vitro-translated 35S-labeled Tat and cold SATB1 were mixed and immunoprecipitated with normal rabbit serum (lane 1 and
3), anti-SATB1 (lane 2), and anti-Tat (lane 4). The immunoprecipitated proteins were detected by autoradiography (left panel) or immunoblot
analysis using anti-SATB1 (right panel). NRS, normal rabbit serum; IP, immunoprecipitation, IB, immunoblot. (C) SATB1 immunoprecipitated
using anti-Tat antibody in extract from NL4.3-infected CEM-GFP cells (lane 2) was detected by immunoblot analysis using anti-SATB1. Lane 3
(C, control) shows proteins in cell extract used for coimmunoprecipitation. The lower panel represents an immunoblot with anti-Tat. (D) Yeast
two-hybrid analysis. Various constructs used for yeast two-hybrid analyses are schematically represented above the two plates depicting growth of
cotransformants. Panels 1 and 2 and 7 and 8 represent the cotransformation of Gal4-AD:SATB1 and Gal4-AD:PDZ with Gal4-DBD:Tat,
respectively. Panels 3 and 9 represent p53 and T antigen as positive controls, 4 and 10 represent p53 and lamin C as negative controls, 5 and 11
represent the Gal4-AD:MDHD and Gal4-DBD:Tat cotransformation, and 6 and 12 represent the mock-transformed cells as controls. (E) De-
lineation of the interaction domain of Tat with SATB1. Nuclear extracts from Jurkat cells were passed separately on GST-fused Tat 20–72, 1–45,
30–72, and 40–72 truncations and GST-Tat C22G mutant affinity columns. Bound proteins were eluted from the GST-Tat affinity column with
phosphate buffer containing 1 M NaCl (lanes 1 to 5, top panel) or with reduced glutathione (lanes 1 to 5, lower panel). Salt-eluted proteins were
subjected to Western blotting using anti-SATB1 (upper panel), whereas proteins eluted with reduced glutathione were subjected to immunoblot
analysis using anti-GST (lower panel).
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manner by using buffers containing 1 M NaCl or reduced
glutathione. The eluted protein was analyzed by SDS-PAGE
followed by immunoblotting using anti-SATB1 (Fig. 5A, lanes
1 to 5 and lanes 11 to 14, upper panel) or anti-GST (Fig. 5A,
lanes 6 to 10) antibody. Their coelution (Fig. 5A, lanes 3 and
13, upper panel) suggested association between SATB1 with
Tat. In HEK 293 cell-free lysates probed with anti-SATB1, we
often observed two closely migrating bands (Fig. 5A, lane 11,
upper panel). Control experiments using GST-bound glutathi-
one Sepharose beads did not yield anti-SATB1 cross-reactive
species (Fig. 5A, lane 5). Only GST was eluted from this
column after elution with buffer containing glutathione (Fig.
5A, lane 10). We then tested the possibility of physical inter-
action between these two proteins by incubating in vitro-trans-
lated Tat with Jurkat cell-free lysate. By coimmunoprecipita-
tion using polyclonal antibodies against each protein, we
observed that SATB1 and Tat formed a complex in vitro (Fig.
5B, lanes 2 and 4). The interaction of these two proteins was
further confirmed by coimmunoprecipitation using cell-free
lysates from NL4.3-infected CEM-GFP cells. Anti-Tat anti-
body immunoprecipitated SATB1 in these lysates, indicating
that SATB1 directly interacts with Tat in vivo (Fig. 5C, lane 2).
Their in vivo functional interaction was further demonstrated
by yeast two-hybrid assays. In a manner that is identical to
coimmunoprecipitation of these with HDAC1 (Fig. 4B), we
found that both the full-length SATB1 (Fig. 5D, panels 2 and
8) and the PDZ domain of SATB1 (Fig. 5D, panels 3 and 9)
interacted with Tat. The MD and HD domains failed to inter-
act with Tat (Fig. 5D, panels 4 and 10). The strength of this
interaction was quantified by a -Gal assay. The interaction of
full-length SATB1 with Tat yielded a value of 41.2 U while that
of PDZ domain and Tat yielded 26.7 U in contrast to the
undetectable -Gal activity of MD and HD, and Tat cotrans-
formed yeast cells. Thus, these results suggest that functional
interaction between HIV-1 Tat and SATB1 occurs via the
PDZ-like domain. We then delineated the interaction domain
of Tat with SATB1 by GST pulldown assay using truncations of
Tat fused with GST. SATB1 was pulled down by Tat 20-72
(Fig. 5E, lane 1) and 1-45 (Fig. 5E, lane 2) but not by Tat 30-71
(Fig. 5E, lane 3) or Tat 40-72 (Fig. 5E, lane 4). Results of this
experiment indicated that a region of 20 to 40 amino acids
representing a part of transactivation domain of Tat is respon-
sible for interaction with SATB1. Additionally, the transacti-
vation-deficient mutant C22G is capable of binding to SATB1
(Fig. 5E, lane 5). Next we tested whether SATB1 and Tat
associate with each other in vivo by indirect immunofluores-
cence using antibodies against each protein. When Tat was
expressed in HEK 293 cells by transient transfection it was
found to colocalize with endogenous SATB1 by indirect im-
munofluorescence analysis. Interestingly, when SATB1 was ex-
pressed exogenously along with Tat in the human breast cancer
cell line SK-BR-3, which does not express SATB1 endog-
enously, a similar nuclear colocalization pattern was observed.
In both cell types, the colocalization was evident in more than
90% of Tat-expressing cells (data not shown).
HIV-1 Tat competitively displaces SATB1-bound HDAC1 in
vitro. To evaluate the functional significance of the interaction
of Tat with SATB1, we asked whether it would bind to SATB1
that had been complexed with HDAC1. We formed a complex
between SATB1 and FLAG-HDAC1 in vitro, captured it with
anti-FLAG affinity beads, and then incubated it with increasing
amounts of purified GST-Tat. The protein bound to HDAC1
was collected using the FLAG beads and subjected to immu-
noblot analysis using anti-SATB1 (Fig. 6A, upper panel) or
anti-HDAC1 (Fig. 6A, lower panel). Interestingly, GST-Tat
displaced the HDAC1-bound SATB1 in a dose-dependent
manner (Fig. 6A, lanes 2 and 3, upper panel), while GST alone
at equivalent or higher concentrations did not (Fig. 6A, lanes
5 and 6, upper panel). To test whether the displacement of
HDAC1 is really due to interaction of Tat with SATB1, we
performed a displacement assay using the C22G mutant Tat, a
point mutant of Tat that is transactivation defective (reviewed
in reference 24), and truncations such as 20–72, 30–72, and
40–72. Strikingly, only the 20–72 truncated version of Tat, not
the others, was able to displace HDAC1 from SATB1 (Fig. 6B,
top panel, lane 4 versus lanes 8 and 10). This result is in perfect
agreement with our protein interaction domain studies (Fig.
5E) suggesting that the displacement of HDAC1 is an outcome
FIG. 6. Tat displaces SATB1-bound HDAC1 in vitro. (A) A com-
petition assay was performed to analyze the binding of HDAC1 and
Tat to SATB1 in vitro. The SATB1-HDAC1 complex was isolated
using anti-FLAG affinity beads in the FLAG pulldown assay as de-
scribed in Materials and Methods (lane 1). The complex was incubated
with 2 and 4 g of recombinant GST-Tat and pulled down using FLAG
beads (lanes 2 and 3, respectively). Lane 4 represents the input lysate.
As a control, the complex was incubated with 2 and 10 g of purified
GST and pulled down with FLAG beads (lanes 5 and 6). The lower
panel represents an immunoblot analysis of these samples using anti-
HDAC1. (B) A competition assay was performed to analyze the
HDAC1-displacing ability of mutant and truncated Tat from the
HDAC1-SATB1 complex in vitro. 293 cells were transiently trans-
fected with FLAG-HDAC1, and the SATB1-HDAC1 complex was
isolated using anti-FLAG affinity beads in the FLAG pulldown assay.
The complex was incubated with 2 and 4 g of recombinant wild-type
GST-Tat (lanes 1 and 2), GST-Tat 20–72 (lanes 3 and 4), GST-Tat
30–72 (lanes 7 and 8), and GST-Tat 40–72 (lanes 9 and 10, respec-
tively) and pulled down using FLAG beads. In the case of pulldown
using the GST-Tat C22G mutant, 2 and 8 g of protein were used
(lanes 5 and 6, respectively). The middle panel represents the purified
GST-Tat proteins stained with Coomassie brilliant blue. The lower
panel represents an immunoblot analysis of these samples using anti-
HDAC1 and serves as loading control.
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of SATB1-Tat interaction. Furthermore, the C22G mutant Tat
displaces HDAC1, albeit with much lower efficiency than wild-
type Tat (Fig. 6B, compare lanes 6 and 2). Despite the use of
double the amount (8 g) of C22G Tat compared to others,
complete displacement is not observed, suggesting a weakened
interaction.
Tat displaces SATB1-bound HDAC1 in HIV-1-infected T
cells, resulting in increased acetylation of the promoters. To
ascertain whether the displacement occurs in vivo, we per-
formed a coimmunoprecipitation assay with cell-free lysate
from NL4.3-infected CEM-GFP cells. SATB1 was associated
with HDAC1 in control uninfected CEM-GFP cells (Fig. 7A,
lane 2). However, in NL4.3-infected cells, SATB1 was not
immunoprecipitated by anti-HDAC1, indicating that HIV-1
Tat disrupts the SATB1-HDAC1 complex in vivo (Fig. 7A,
lane 4). We then performed a ChIP assay to analyze whether
SATB1 recruits HDAC1 to the IL-2 and IL-2R upstream
regions in vivo. SATB1 was bound to these promoters in both
uninfected (Fig. 7B and C, top panels, lanes 1) and NL4.3-
infected (Fig. 7B and C, top panels, lanes 2) CEM-GFP cells.
HDAC1 was recruited in vivo to the promoters in uninfected
cells (Fig. 7B and C, middle panels, lanes 1). In contrast,
HDAC1 was not recruited to the promoters in NL4.3-infected
cells (Fig. 7B and C, middle panels, lanes 2). ChIP analysis
using anti-Tat immunoprecipitated chromatin revealed that
Tat is bound to the promoter only in infected cells (Fig. 7E and
F, top panels, lanes 2) but not in uninfected cells (Fig. 7E and
F, top panels, lanes 1), consistent with its expected expression
pattern. We then monitored the acetylation status of IL-2 and
IL-2R promoters by ChIP analysis using antibody against
acetylated lysine 9 of histone H3 (H3-K9). We observed that
the promoter chromatin was specifically acetylated in vivo in
FIG. 7. Tat displaces SATB1-bound HDAC1 in HIV-1 infected T cells, leading to increased acetylation of promoters. (A) Coimmunoprecipi-
tation (Co-IP) analysis using extracts from uninfected (lanes 1 and 2) and NL4.3-infected (lanes 3 and 4) CEM-GFP cells. Immunoprecipitation
was carried out using mouse IgG1 (lanes 1 and 3) and anti-HDAC1 antibody (lanes 2 and 4). As a control, a mixture of normal rabbit IgG and
mouse monoclonal IgG1 was used (lane 3). IB, immunoblotting. (B and E) ChIP analysis of IL-2 promoter. PCR amplification of DNA isolated
from immunoprecipitated chromatin was performed as described above by using the IL-2-P1 primer pair. The antibodies used for immunopre-
cipitation are as indicated. UI, uninfected; I, infected; C, control. (C and F) ChIP analysis of the IL-2R promoter. DNA isolated from
immunoprecipitated chromatin from the uninfected and infected CEM cells using anti-SATB1, anti-HDAC1, anti-Tat, and anti-acetylated H3-K9
antibodies were PCR amplified. Input represents PCR amplification of the DNA in total cross-linked chromatin. (D) ChIP analysis of the IL-2
promoter was performed using anti-SATB1 immunoprecipitated chromatin and IL-2-P1 (middle panel) and IL-2-P2 (upper panel) primer pairs.
(G) As a control, normal rabbit IgG (middle panel) and mouse monoclonal IgG1 (upper panel) were used for immunoprecipitation of cross-linked
chromatin, and DNA in the immunoprecipitate was amplified using the IL-2-P1 primer pair. ChIP analysis of chromatin from uninfected and
HIV-1-infected PBMCs was also performed using primers specific for IL-2 (H and I) and IL-2R (J and K) promoters. The antibodies used for
immunoprecipitation were as indicated. Quantification of immunoprecipitated chromatin was performed by real-time PCR analysis. The changes
in amount of immunoprecipitated chromatin ( Ct) were calculated as described in Materials and Methods. Values from three independent ChIP
experiments were plotted for the IL-2 (L) and IL-2R (M) promoters. The antibodies used for ChIP are anti-SATB1 (1 and 2), anti-HDAC1 (3 and
4), anti-Tat (5 and 6), and anti-histone H3 acetyl lysine 9 (7 and 8). Solid and empty bars indicate infected and uninfected samples, respectively.
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the infected cells (Fig. 7E and F, middle panels, lanes 2). In
contrast, a minimal level of acetylation was observed in unin-
fected cells (Fig. 7E and F, middle panels, lanes 1). Interest-
ingly, the proximal promoter region of IL-2 spanning base
pairs 	315 to  1 was not occupied by SATB1 in both unin-
fected and infected CEM-GFP cells (Fig. 7D, top panel) while
the distal IL-2 promoter spanning base pairs 	575 to 	292 is
bound by SATB1 (Fig. 7D, middle panel). Strikingly, the same
pattern of HDAC1 displacement at the IL-2 (Fig. 7H) and
IL-2R (Fig. 7J) promoters was observed in NL4.3-infected
primary T cells. Furthermore, ChIP analysis also revealed el-
evated levels of acetylation of the promoters (Fig. 7I and K, top
panels) in infected PBMCs. To validate our findings further,
we performed quantification of immunoprecipitated chroma-
tin by real-time PCR analysis. Infection did not result in any
significant change in SATB1 occupancy at both promoters
(Fig. 7L and M, lanes 1 and 2). However, HDAC1 occupancy
was decreased at least fourfold as evidenced by an increase in
CT values by a factor of about 2 (Fig. 7L and M, lanes 3 and 4).
A decrease in CT value of 1 U corresponds to a twofold in-
crease in template copy number. As expected, Tat occupancy
increased upon infection (Fig. 7L and M, lanes 6) and was
undetectable in uninfected samples (Fig. 7L and M, lanes 5).
Interestingly, when we used anti-histone H3 acetyl lysine 9
antibody to check the level of promoter acetylation, we ob-
served a fourfold increase in the acetylation of IL-2R pro-
moter upon infection (Fig. 7M, lanes 7 and 8), and about a
sixfold increase in the acetylation of IL-2 promoter upon in-
fection (Fig. 7L, lanes 7 and 8) as evidenced by the decrease in
CT value. Collectively, these results indicated that Tat-medi-
ated displacement of HDAC1 in the infected cells may be
responsible for the observed derepression of IL-2 and IL-2R.
Soluble Tat upregulates IL-2 and IL-2R and increases the
acetylation status of IL-2 and IL-2R promoters in Jurkat T
cells. To address the question of whether Tat alone could
induce the expression of IL-2 and its receptor, and also to rule
out any other effects of exposure to the virions, we performed
a transduction experiment. The uptake, internalization, and
nuclear translocation of Tat can be used as a tool for protein
delivery (39, 42). We prepared recombinant wild-type Tat and
its truncations as well as mutations as described above (Fig.
8A) and incubated Jurkat cells in media containing these.
Immunoblot analysis using nuclear extracts of Jurkat cells
proved that the proteins had actually entered into the nuclei of
treated cells (Fig. 8B). Flow cytometric analysis of transduced
cells stained using anti-Tat antibody revealed that about 85%
of the cells were positive for Tat (Fig. 8C). Incubation of cells
with Tat resulted in upregulation of IL-2 and IL-2R as evi-
denced by an increase in mRNA levels shown by RT-PCR
analysis (Fig. 8D, lane 3), and RNA from cells incubated with
GST alone served as a control for this RT-PCR experiment
(Fig. 8D, lane 1). However, when cells were incubated with the
40–72 truncation of Tat that is deficient in interaction with
SATB1 (Fig. 5E), such an increase in the levels of IL-2 or
IL-2R transcript levels was not observed (Fig. 8D, lane 2).
Interestingly, under these conditions we found a reciprocal
relationship between the HDAC1 occupancy and acetylation
level of H3-K9 (Fig. 8E). We observed an increase in the level
of acetylation of H3-K9 specifically in the presence of Tat (Fig.
8E, lanes 2 and 8) and its SATB1-interacting derivatives (lanes
6 and 12), including the C22G Tat mutant (lanes 5 and 11).
Interestingly, Tat protein deficient in interaction with SATB1
(Tat 40–72) is unable to displace HDAC1 and induce acetyla-
tion at the promoters (Fig. 8E, lanes 4 and 10), whereas trans-
activation-defective Tat C22G is capable of displacing HDAC1
and inducing promoter acetylation, albeit to a lesser extent
than wild-type Tat. These results indicate that Tat alone is
responsible for induction of IL-2 and its receptor and that the
interaction of Tat with SATB1 is necessary for this upregula-
tion.
Tat-mediated displacement of HDAC1 causes derepression
of IL-2 and IL-2R in vivo. For direct assessment of the reg-
ulatory activity of SATB1 and Tat at the IL-2 and IL-2R
promoters, we performed luciferase reporter assays. The
632-bp promoter region of IL-2 (Fig. 9A) and the 555-bp
promoter region of IL-2R (Fig. 9B) were used in conjunction
with the promoterless luciferase reporter vector pGL3basic.
We transiently expressed SATB1 in 293 cells and cotransfected
them with constructs expressing HDAC1 and Tat. SATB1 ex-
pression (Fig. 9A and B, lanes 2) downregulated these pro-
moters individually and synergistically with HDAC1 (Fig. 9A
and B, lanes 5). However, when cells were cotransfected with
Tat, the repression mediated by SATB1 was alleviated (Fig. 9A
and B, lanes 7) and was comparable to that of Tat alone (Fig.
9A and B, lanes 4). This may be attributed to the displacement
of endogenous HDAC1 that is complexed with exogenously
introduced SATB1. HDAC1 alone was not able to repress the
transactivation by Tat to a significant extent (Fig. 9A and B,
lanes 6). To unequivocally demonstrate the role of Tat in
displacement of HDAC1 and thereby the derepression of the
IL-2 and IL-2R, we used the transactivation-deficient mutant
Tat C22G. We performed reporter assays using wild-type Tat
and the above-mentioned mutants of Tat. We found that al-
though C22G Tat is defective in transactivation, it is able to
derepress both IL-2 and IL-2R in a dose-dependent manner
(Fig. 9A and B, lanes 5 and 6). In fact, with 2 g of C22G Tat,
the derepression occurs such that the activity is almost back to
the level of SATB1 alone (Fig. 9A and B, lanes 6). This dose-
dependent effect further supports our finding that Tat and
HDAC1 compete for binding to SATB1 in vivo. Wild-type Tat
derepresses IL-2 and IL-2R by about fourfold (Fig. 9A and B,
lanes 7). Collectively, these results suggest that the T-lineage-
specific protein SATB1 is the common factor involved in the
regulated expression of IL-2 and IL-2R and that Tat causes
derepression and induction of IL-2 and IL-2R in the presence
of SATB1.
DISCUSSION
HIV-I- and HTLV-1-infected CD4 T cells are activated
and proliferate during the initial phase of infection that is
accompanied by dysregulation of multiple genes (7, 18). The
retroviral infection is limited by the quiescence of most circu-
lating T cells that are therefore nonsupportive of viral replica-
tion. Formation of integrated provirus is obligatory for viral
replication and subsequent development of AIDS (13, 31, 47,
51, 54). The barrier for integration observed in host peripheral
T cells can be overcome by T-cell activation (47). Recent
studies have shown that expression of the earliest HIV gene
products, Nef and Tat, can increase T-cell activity (34, 41, 50).
VOL. 25, 2005 HIV-1 Tat DISRUPTS SATB1-HDAC1 COMPLEX 1629
Nef acts by lowering the activation threshold in T cells (41),
while Tat acts by deregulating the expression of several host
genes, including proto-oncogenes and genes encoding meta-
bolic enzymes, cytokines, and cytokine receptors (5, 7, 12, 18,
40). Recent studies by Wu and Marsh solved the puzzle of how
these proteins would function in the absence of viral replica-
tion. They reported that nef and tat genes are selectively tran-
scribed in infected cells before integration (52). Thus, the early
events of HIV infection induce the IL-2 and IL-2R protein
levels that are required for rapid proliferation of active T-cells
which subsequently become the most preferable target cells for
HIV infection. In the later episodes of HIV infection, infected
T cells undergo apoptosis, and this may be responsible for the
sudden decrease in T-cell numbers and the resulting drop in
immunity of the infected patient. This is one of the host-
pathogen interactions in which virus initially takes advantage
of the host machineries for its efficient infection and rapid
proliferation of host T cells. However, the molecular mecha-
nisms of how this is accomplished, and especially the contri-
bution of host factors, are not completely understood.
Tat activates host and viral transcription by recruiting host
transcription factors and coactivators (7). Contradictory obser-
FIG. 8. Transduction of soluble Tat upregulates IL-2 and IL-2R and increases the acetylation status of IL-2 and IL-2R promoters in Jurkat
T cells. (A) SDS–15% PAGE analysis of purified recombinant Tat proteins. Wild-type Tat (lane 5), Tat 1–48 (lane 3), Tat 40–72 (lane 4), and C22G
mutant Tat (lane 7) were expressed as GST fusions in BL21 cells and purified as described in Materials and Methods. Tat (lane 6) and GST (lane
2) were obtained by thrombin cleavage. B. Recombinant GST-Tat (lane 1) and Tat (lane 2) proteins were transduced separately into Jurkat cells,
and nuclear lysates were prepared as described in Materials and Methods. The nuclear lysates were resolved by electrophoresis in 15%
SDS–polyacrylamide gels followed by Western blot analysis using anti-Tat antibody. (C) Flow cytometric (FACS) analysis of transduced cells. Cells
incubated with 100 ng of recombinant Tat for 4 h were immunostained using rabbit IgG (upper histogram) or anti-Tat (lower histogram) and
acquired on a flow cytometer as described in Materials and Methods. (D) RT-PCR analysis of mRNA from transduced cells. Total mRNA was
isolated from Jurkat cells incubated with GST (lane 1), GST-Tat 40-72 (lane 2), and GAT-Tat (lane 3). RT-PCR analysis was performed using IL-2
(upper panel), IL-2R (middle panel), and GAPDH (lower panel) cDNA primers. (E) HDAC1 occupancy and promoter acetylation are inversely
correlated. To monitor the acetylation status of IL-2 and IL-2R promoters independent of HIV-1 virion exposure, we transduced the wild-type Tat
(lanes 2 and 8), GST (lanes 3 and 9), Tat-40-72 (lanes 4 and 10), Tat-C22G (lanes 5 and 11), and Tat-1-48 (lanes 6 and 12) proteins into Jurkat
cells as described in Materials and Methods. Chromatin was then prepared and subjected to ChIP analysis using anti-SATB1, anti-HDAC1, and
anti-H3 acetylated lysine 9 antibodies. As negative and positive controls we used rabbit IgG (R-IgG, lanes 1 and 7) and input chromatin (bottom
panels), respectively.
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vations describe the regulation of IL-2 and its receptor by Tat
(19, 46, 36, 37). However, in studies where the expression of
IL-2 and its receptor have been shown to be downregulated by
Tat, stable expression of Tat was employed (36, 37). Lympho-
cytes from HIV-1 infected patients are known to express in-
creased amounts of IL-2 and IL-2R (18, 43). We therefore
argued that the molecular mechanism of this phenomenon
could not be elucidated using only Tat-transfected T cells.
Here, we have used HIV-1 infected T cells and evaluated the
role of SATB1, a T-lineage-specific transcription factor (2), in
the regulation of IL-2 and IL-2R expression. Studies utilizing
SATB1 null mice have established SATB1 as a new type of
gene regulator responsible for a novel cagelike nuclear archi-
tecture, providing sites for tissue-specific organization of DNA
sequences and regulating region-specific histone modification
(6). SATB1 is a predominant architectural protein in T cells
(2) that functions as a global suppressor by targeting chromatin
remodeling to regulate genes over long distances (53). We
therefore reasoned that Tat would have to overcome the tran-
scriptional suppression mediated by SATB1 in a manner that
would allow activation of genes required for viral replication
and T-cell activation.
The activation dependence and cell type specificity of IL-2
expression are mediated through a dynamic assembly of di-
verse transcription factors, including NF-AT, NF-B, AP-1,
and Oct-1 at its promoter (38). Likewise, several studies have
demonstrated the presence of multiple protein binding sites
within the IL-2R upstream regulatory sequences in the region
of base pairs 	476 to 	225 (28, 30). We have identified, for
the first time, SATB1 binding sites in the promoters of IL-2
and its receptor. Furthermore, we narrowed down these bind-
ing sites to the IDR in the IL-2R promoter and a 37-mer
ATC sequence in the IL-2 promoter. SATB1 may also bind to
additional regions within these promoters; however, the pres-
ence of these two elements is essential since deletions of these
elements abolish binding to longer overlapping regions. Stud-
ies using chromatin from thymocytes of wild-type and SATB1
null mice demonstrated the presence of a strong intronic
SATB1 binding site within the IL-2R locus and a weak bind-
ing site within the promoter (53). In the present study, we have
narrowed down the binding site for SATB1 in the human
IL-2R promoter and demonstrate that it consists of the IDRs
flanking the B-like motif. Whether a similar binding site pref-
erence is exhibited by SATB1 in the mouse IL-2R promoter
remains to be investigated. In most of the earlier studies, con-
tribution of specific transcription factors has been evaluated by
using their minimal binding sites in the upstream regulatory
regions of IL-2 and IL-2R (9, 19, 28, 30, 38, 46). We used
regions of more than 500 bp to analyze the role of SATB1,
ensuring that the promoters may be simultaneously occupied
by other transcription factors whose contribution was consid-
ered as the baseline. Our data demonstrate that SATB1 binds
to the upstream regulatory elements of IL-2 and IL-2R and
negatively regulates their expression. We monitored IL-2 levels
in infected PBMCs by RT-PCR analyses and observed that
IL-2 expression peaks around day 4 postinfection and then
gradually decreases with time (our unpublished observation).
However, monitoring the expression of IL-2 in PBMCs in-
fected in the presence of IL-2 is more complicated due to the
fact that exogenously added IL-2 exerts diverse effects on virus
FIG. 9. Tat-mediated derepression of IL-2 and IL-2R transcrip-
tion in 293 cells exogenously expressing SATB1, HDAC1, and Tat. The
effect of Tat mutants in the derepression of IL-2 (A) and IL-2R (B) is
shown. A luciferase (Luc) reporter assay was performed upon cotrans-
fections of 1 to 2 g of various expression constructs along with
IL-2-luciferase (A) or IL-2R-luciferase (B) reporter constructs. Cells
were harvested 40 h after transfection, and luciferase activity was
measured using 50 g of protein from each cell lysate. Luciferase
activity is expressed as increase or decrease compared to the control
(lane 1), which was set to baseline. Lane 1, reporter construct alone;
lane 2, SATB1; lane 3, SATB1  HDAC1; lane 4, Tat C22G; lane 5,
SATB1HDAC1 C22G (1 g); lane 6, SATB1HDAC1 C22G
(2 g); lane 7, wild-type Tat (WT-Tat); lane 8, SATB1  HDAC1 
Tat. Data from triplicates are plotted, and relative luciferase units are
represented as increase or decrease in activity with respect to the
reporter alone. The statistical significance of differences between the
treatment groups was calculated using one-way analysis of variance,
and the observed P values were always less than 0.001. (C) Model
depicting HDAC1 displacement following Tat transfection. In the ab-
sence of Tat, SATB1 represses transcription of the reporter by recruit-
ing the HDAC1 corepressor. When Tat is introduced, it binds to the
PDZ-like domain of SATB1 and displaces HDAC1, thereby stimulat-
ing transcription. For details, see the text.
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production (3) and the impaired IL-2 production during HIV
disease may be attributed to a feedback mechanism wherein
IL-2 induces CD8 HIV suppressors (26). However, Tat was
previously shown to derepress the IL-2 promoter (12), and the
derepression is very clearly observed in the case of infected
CEM cells.
SATB1 contains an MD and an HD towards the carboxy-
terminal half, which confer the ability to recognize the core-
unwinding element within a BUR element (10, 33). SATB1
harbors a novel dimerization domain in its N-terminal region,
which is homologous to PDZ domains (16). Recently SATB2,
a homolog of SATB1, was identified; it also possesses the
PDZ-like domain (our unpublished observations). However,
SATB2 is specifically expressed in brain, testis, kidney, pre-B
cells, and B cells but not in T cells (11); therefore, it may not
play a role in HIV pathogenesis at least during the early stages
of infection. PDZ domains are protein interaction modules
that are implicated in signal transduction (14). Both HDAC1
and Tat bind SATB1 via this protein interaction domain.
SATB1 interacts with the transactivation domain of Tat, a
domain that is known to associate with many of Tat’s interac-
tion partners (reviewed in reference 24). Thus, the competition
within these factors would eventually determine the outcome
of such interactions. Through direct physical interaction, Tat
competitively displaces SATB1-bound HDAC1 in vivo. Strik-
ingly, the transcriptional upregulation of IL-2 and IL-2R does
not require the transactivation function of Tat. In the case of
Tat-mediated regulation of LTR, the transcriptional activation
is associated with remodeling of nucleosome 1 by acetylation.
ChIP studies by He and Margolis suggested that histone acetyl-
transferases or other factors recruited to LTR by Tat may
interact with HDAC1, YY1, or both and may regulate their
functions or interaction (23). Furthermore, treatment with tri-
chostatin A or Tat transfection decreased HDAC1 occupancy
at the LTR, presumably via displacement. However, further
study is required to define the mechanisms by which trichos-
tatin A and Tat decrease HDAC1 occupancy at the LTR.
Histone acetylation is typically associated with transcrip-
tional activation (reviewed in reference 4). Consequently, we
reasoned that the loss of HDAC1 from the IL-2 and IL-2R
promoters might likely lead to an increase in acetylation at the
regulatory regions. We observed that the promoter chromatin
was specifically acetylated in vivo in the infected cells, suggest-
ing remodeling of the promoter to favor transcription. In the
absence of Tat, SATB1 represses transcription of IL-2 and its
receptor by recruiting the HDAC1 corepressor, which could be
in the form of a larger repressor complex, and thereby pro-
motes deacetylation of the promoter and represses transcrip-
tion. When Tat is introduced either via HIV-1 infection or by
transfection or transduction, it binds to the PDZ-like domain
of SATB1 and competitively displaces HDAC1. Tat may fur-
ther recruit the CBP/p300 histone acetyltransferase to promote
acetylation of the promoter, thereby stimulating transcription
(model depicted in Fig. 9C). Interestingly, transduction exper-
iments using soluble Tat and its derivatives clearly demon-
strated an inverse correlation between HDAC1 occupancy and
acetylation of promoter chromatin and resulted in induction of
IL-2 and its receptor, corroborating our hypothesis that com-
petitive displacement of SATB1-bound HDAC1 by Tat is the
cause for upregulation of IL-2 and its receptor. Our results
further suggest that the induction of transcription may occur by
abolition of the repressor function in addition to the induction
of host factors upon viral infection. We propose that this mech-
anism may be employed by HIV-1 to overcome the SATB1-
mediated repression of genes essential for its propagation in T
cells.
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